ALK Inhibitors, a Pharmaceutical Perspective

Por Ardini, Elena, Galvani, Arturo
Publicado em 2012

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Por Amatu, Alessio, Somaschini, Alessio, Cerea, Giulio, Bosotti, Roberta, Valtorta, Emanuele, Buonandi, Pasquale, Marrapese, Giovanna, Veronese, Silvio, Luo, David, Hornby, Zachary, Multani, Pratik, Murphy, Danielle, Shoemaker, Robert, Lauricella, Calogero, Giannetta, Laura, Maiolani, Martina, Vanzulli, Angelo, Ardini, Elena, Galvani, Arturo, Isacchi, Antonella, Sartore-Bianchi, Andrea, Siena, Salvatore
Publicado no Br J Cancer (2015)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Por Sartore-Bianchi, Andrea, Ardini, Elena, Bosotti, Roberta, Amatu, Alessio, Valtorta, Emanuele, Somaschini, Alessio, Raddrizzani, Laura, Palmeri, Laura, Banfi, Patrizia, Bonazzina, Erica, Misale, Sandra, Marrapese, Giovanna, Leone, Antonella, Alzani, Rachele, Luo, David, Hornby, Zachary, Lim, Jonathan, Veronese, Silvio, Vanzulli, Angelo, Bardelli, Alberto, Martignoni, Marcella, Davite, Cristina, Galvani, Arturo, Isacchi, Antonella, Siena, Salvatore
Publicado no J Natl Cancer Inst (2015)

Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Por Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M., Farago, Anna F., Wheler, Jennifer J., Liu, Stephen V., Doebele, Robert, Giannetta, Laura, Cerea, Giulio, Marrapese, Giovanna, Schirru, Michele, Amatu, Alessio, Bencardino, Katia, Palmeri, Laura, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Cresta, Sara, Damian, Silvia, Duca, Matteo, Ardini, Elena, Li, Gang, Christiansen, Jason, Kowalski, Karey, Johnson, Ann, Patel, Rupal, Luo, David, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S., Shaw, Alice T., De Braud, Filippo G.
Publicado no Cancer Discov (2017)